ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
bullish•Hang Seng Index
•10 Jan 2026 10:21

Hong Kong Single Stock Options Weekly (Jan 05 – 09): Dispersion Over Direction

Index level calm contrasts with active stock level dynamics, where options positioning and volatility reveal a market driven by dispersion rather...

Logo
John Ley
237 Views
Share
•09 Jan 2026 11:45

Hong Kong Buybacks Weekly (Jan 9th): Tencent, Xiaomi, Geely Automobile

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
274 Views
Share
•06 Jan 2026 07:12

Hang Seng Biotech Index Rebalance Preview: One Set of Changes in March

TransThera Sciences could replace Everest Medicines in the index in March. Plus some capping changes. Estimated one-way turnover is 2.1% and the...

Logo
644 Views
Share
•05 Jan 2026 09:05

Hong Kong Buybacks Weekly (Jan 2nd): Tencent, Xiaomi, Cosco Shipping

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
330 Views
Share
•26 Dec 2025 11:27

Hong Kong Buybacks Weekly (Dec 26th): Tencent, Xiaomi, Kuaishou

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
272 Views
Share
x